Abstract
Canertinib, a water-soluble, orally available analog of PD-169414 (Pfizer Inc), is an EGFR tyrosine kinase inhibitor under development by Pfizer Inc as a potential treatment for cancer.
MeSH terms
-
Angiogenesis Inhibitors / adverse effects
-
Angiogenesis Inhibitors / pharmacokinetics
-
Angiogenesis Inhibitors / therapeutic use*
-
Angiogenesis Inhibitors / toxicity
-
Animals
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Agents / toxicity
-
Clinical Trials, Phase I as Topic*
-
Humans
-
Morpholines / adverse effects
-
Morpholines / pharmacokinetics
-
Morpholines / therapeutic use*
-
Morpholines / toxicity
-
Neoplasms / drug therapy*
-
Structure-Activity Relationship
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Morpholines
-
Canertinib